Impacto do tratamento intravenoso com sacarato de hidróxido de ferro IIInos marcadores séricos de deficiência de ferro e na hemoglobina sérica em pacientes com doença renal crônica pré-dialítica / Impact of intravenous iron sucrose treatment upon serum markersof iron deficiency and serum hemoglobin in patients with chronic kidney disease not on dialysis
J. bras. nefrol
;
29(1): 33-37, Mar. 2007. tab
Article
Dans Portugais
| LILACS
| ID: lil-605326
ABSTRACT
Anemia is a frequent complication of CKD and has numerous physiologic effects. In the treatment of anemia it is important to guarantee adequate iron storesfor hemoglobin synthesis. The aim of this study is to report on the impact of iron reposition on hemoglobin levels in patients with CKD stages 3 to 5. Fortyanemic patients (hemoglobin <11.0 g/dL) with CKD stages 3 (17,5%), 4 (58,5%), and 5 (25%), not receiving re-Hu-Erithropoetin were treated with IV iron(Noripurum, Altana Pharma), a ferric sucrose product. Iron deficiency was diagnosed when transferrin saturation was <20% and/or ferritin <100 mg/L. TheIV Iron (100 mg/ ampoules) was given in 150 mL of saline over 90 minutes. Glomerular filtration rate (GFR) was estimated from serum creatinine using theMDRD formula, and patients were categorized according to the stages defined by K/DOQI of the NKF. The mean age of the patients was 58.6±17 yearsand 56% were female. The main causes of CKD were hypertension (33.0%), diabetes mellitus (19.0%) and glomerulonephritis (19.0%). The mean valuesof the lab results before and after the IV iron administration were creatinine (2.79±1.28 and 3.01±1.84, p>0.90), GFR (25.92±13.4 and 26.14±13.34, p>0.29), serum iron (58.3±28 and 90.9, p>0.60), transferrin saturation index (22.94±11.36 and 27.4±8, p>0.49), ferritin (84.69±78.3 and 164.8±141, p<0.04) andhemoglobin (9.52±1.24 and 10.53±1.44, p<0.000). The mean amount of IV iron sucrose administered was 319±180mg. The IV iron was very well toleratedand no serious side effect was observed. In conclusion, administration of IV Noripurum, a dextran-free iron compound, was safe and showed a beneficial impact on the hemoglobin level, and its use optimized the treatment of anemia in patients with CKD.
Recherche sur Google
Indice:
LILAS (Amériques)
Sujet Principal:
Anémie par carence en fer
/
Fer
/
Défaillance rénale chronique
Type d'étude:
Études d'évaluation
/
Guide de pratique
Limites du sujet:
Adulte
/
Femelle
/
Humains
/
Mâle
langue:
Portugais
Texte intégral:
J. bras. nefrol
Thème du journal:
Néphrologie
Année:
2007
Type:
Article
Pays d'affiliation:
Brésil
Institution/Pays d'affiliation:
Universidade Federal de Juíz de Fora/BR
Documents relatifs à ce sujet
MEDLINE
...
LILACS
LIS